Marked efficacy of combined three-drug therapy (Sodium Valproate, Topiramate and Stiripentol) in a patient with Dravet syndrome

M Morimoto; S Shimakawa; T Hashimoto; T Kitaoka; S Kyotani

doi:10.1111/jcpt.12659

Marked efficacy of combined three-drug therapy (Sodium Valproate, Topiramate and Stiripentol) in a patient with Dravet syndrome

J Clin Pharm Ther. 2018 Aug;43(4):571-573. doi: 10.1111/jcpt.12659. Epub 2017 Dec 18.

Authors

M Morimoto¹, S Shimakawa¹, T Hashimoto¹, T Kitaoka², S Kyotani²

Affiliations

¹ Japanese Red Cross Tokushima Hinomine Rehabilitation Center for People with Disabilities, Tokushima, Japan.
² Graduate School of Pharmaceutical Sciences, Tokushima Bunri University, Tokushima, Japan.

PMID: 29265387
DOI: 10.1111/jcpt.12659

Abstract

What is known and objective: Dravet syndrome (DS) is an intractable epilepsy syndrome. The three-drug combination therapy of sodium valproate (VPA), clobazam (CLB) and stiripentol (STP) is recommended worldwide.

Case summary: We present a case of DS, in which treatment with CLB could not be continued because of the appearance of adverse reactions to it. Replacement with topiramate (TPM) proved to be markedly effective.

What is new and conclusion: It is suggested that combination therapy with VPA, TPM and STP is for DS epilepsy.

Keywords: Combination Therapy; anti-epileptic drug; dravet syndrome.

Publication types

Case Reports

MeSH terms

Anticonvulsants / adverse effects*
Anticonvulsants / therapeutic use*
Child, Preschool
Dioxolanes / adverse effects
Dioxolanes / therapeutic use
Drug Therapy, Combination / methods
Epilepsies, Myoclonic / drug therapy*
Epilepsy / drug therapy
Female
Fructose / adverse effects
Fructose / analogs & derivatives
Fructose / therapeutic use
Humans
Topiramate
Valproic Acid / adverse effects
Valproic Acid / therapeutic use

Substances

Anticonvulsants
Dioxolanes
Topiramate
Fructose
Valproic Acid
stiripentol